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Protein thermal shift is a relatively rapid and inexpensive technique for the identification of low 4	  
molecular weight compound interactions with protein targets. An increase in the melting 5	  
temperature of the target protein in the presence of a test ligand is indicative of a promising 6	  
ligand:protein interaction. Due to its simplicity, protein thermal shift is an attractive method for 7	  
screening libraries and validating hits in drug discovery programmes. The methodology has 8	  
been used successfully in high throughput screens of small molecule libraries, and its 9	  
application has been extended to report on protein:drug-like-fragment interactions. Here, we 10	  
review how protein thermal shift has been employed recently in fragment-based drug discovery 11	  
(FBDD) efforts, and highlight its application to protein:protein interaction targets. Multiple 12	  
validation of fragment hits by independent means is paramount to ensure efficient and 13	  
economical progress in a FBDD campaign. We discuss the applicability of thermal shift assays 14	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   3	  
 1	  
Introduction 2	  
Protein thermal shift assays (TSA) can report on low molecular weight compound interactions 3	  
with protein targets. This relatively rapid, inexpensive and high throughput method is an 4	  
attractive approach for screening fragment libraries or validating initial hits in small-molecule 5	  
and fragment based drug discovery (FBDD) campaigns.  6	  
 7	  
The principle of a TSA experiment is simple. Protein interactions with environmental 8	  
components can alter (shift) the melting temperature (Tm) of a protein relative to an apo protein 9	  
reference, offering a convenient read-out of protein:compound interactions (Figure 1.) During a 10	  
typical experiment, the target protein is heated in a continuous temperature ramp (typically 25 – 11	  
95 °C) with protein unfolding reported via an environmentally sensitive dye that fluoresces only 12	  
when bound to hydrophobic regions exposed as the protein unfolds 1,2. Protocols co-opt 13	  
standard Real Time PCR instrumentation and use commercially available and affordable 14	  
fluorescent dyes and plasticware making it relatively easy to establish the protocol in any 15	  
laboratory 3,4. Execution is straightforward, and in contrast to NMR, X-ray, SPR or mass 16	  
spectrometry methods requires a greatly reduced degree of technical expertise.  17	  
 18	  
Protocols have been miniaturized 1,3 and can be performed in 384 or 96 well plates, permitting 19	  
final reaction volumes of ≤ 20 and 40 µL respectively. Typical final protein concentrations are in 20	  
the order of 1 - 5 µM making the experiment relatively inexpensive in terms of protein usage. 21	  
Using a temperature ramp rate of 1 - 3 °C min-1, experiments can be completed in 22	  
approximately 30 – 60 min. Furthermore, data analysis can be semi-automated with the use of 23	  
instrument software or customised programs 5 allowing results to be obtained in a single day. 24	  
Tm shifts arising from interactions with small molecules and fragments are frequently small in 25	  
magnitude (<1 – 2 °C), generating narrow margins within which to discriminate hits from non-26	  
hits. In the absence of a known small-molecule binder with which to compare test molecules 27	  
(often the case in de novo screens against new targets), it is accepted practice to define a hit 28	  
	   4	  
interaction as one that yields a Tm shifter greater than 3 times the standard deviation of the 1	  
reference 6. The solvent in which test compounds are dissolved (e.g. DMSO) can itself influence 2	  
protein Tm, often in a destabilizing manner 6. It is thus advised that solvent concentrations are 3	  
kept to a minimum (2 % maximum) and imperative that comparisons of ligand-altered Tms are 4	  
made to solvent-matched controls. Pivotal to the approach is that the target protein yields an 5	  
unambiguous melt curve. Optimization of reaction conditions (e.g. buffer composition, protein 6	  
and dye concentration) may be required to elicit a clear transition curve with a significant 7	  
increase in fluorescence emission during unfolding. The approach is certainly feasible for many 8	  
monomeric proteins (even membrane proteins) 1, and in theory also for oligomeric proteins if 9	  
there are clearly demarcated unfolding transitions of quaternary and tertiary structure. 10	  
 11	  
The stabilizing effect of a compound upon protein thermal stability is proportional to both 12	  
compound concentration and affinity. Ligand binding constants can be determined by 13	  
measuring the effect of increasing ligand concentration on Tm, provided that the 14	  
thermodynamics of protein stability are known with accuracy e.g. from differential scanning 15	  
calorimetry experiments 2. For a given protein, different ligands with equivalent affinities can 16	  
induce different Tm shifts, reflecting ligand specific differences in enthalpic and entropic 17	  
contributions to binding. TSA does not distinguish between enthalpically or entropically driven 18	  
interactions, although larger shifts in Tm are often observed for more entropically (e.g. 19	  
hydrophobic) dominated binding interactions 3. 20	  
  21	  
TSA is a simple technique, with versatile applications.  It has been applied to the identification 22	  
and optimization of buffer formulations that promote protein stability, and which in turn increase 23	  
the likelihood of protein crystallization 7,8. TSA also appears suitable in some cases for the 24	  
detection of heavy atom binding 8 suggesting it has potential as an adjunct to experimental 25	  
phasing in macromolecular crystallography. In the drug discovery arena, the potential for using 26	  
TSA in small-molecule screening was the subject of excited debate more than a decade ago 1,9 27	  
and there have since been several successful applications 6,10,11,12. Its application has since 28	  
	   5	  
been extended to fragment based campaigns 2,3,4.  Today, several stalwarts of FBDD programs 1	  
(e.g. Astex Pharmaceuticals, Vernalis) indicate that they routinely employ TSA in their screening 2	  
pipelines, and a poll of the wider fragment community suggests that it is a popular method 13. As 3	  
with all drug discovery screening, efficient first round screening with follow-up validation of 4	  
fragment hits by independent means is paramount to ensure timely and economical progress in 5	  
the campaign. In this light, TSA is potentially a quick and inexpensive tool that can be used for a 6	  
primary screen or to complement other screening methods. In addition to its relative simplicity, 7	  
TSA offers the advantage that it can identify fragments that have a destabilising effect upon the 8	  
protein (indicated by a reduced rather than an increased Tm)14. However, despite the 9	  
advantages of TSA, (and examples of its application in small molecule screening) the number of 10	  
articles citing its use in FBDD, particularly as a primary screening tool, seem relatively low. In a 11	  
publishing culture where negative results are not routinely reported, it is inherently difficult to 12	  
gauge the extent of unhelpful or uninformative TSA experiences. However it would appear that 13	  
the contribution of TSA to hit identification falls behind that of NMR and SPR, with reports from 14	  
meetings indicating that “of all the methods for finding fragments, thermal shift assays seem to 15	  
be the most controversial 13.”  16	  
 17	  
Here we highlight recent articles that have applied TSA to FBDD and discuss some of the 18	  
successes and associated challenges, with particular interest in its application to protein:protein 19	  
interaction (PPI) targets.  20	  
 21	  
TSA in Fragment Based Drug Discovery  22	  
TSA has been successfully employed as the primary screening tool in three recent academic 23	  
FBDD campaigns against myo-inositol-3-phosphate synthase from Trypanosoma brucei 24	  
(TbINO1) (The University of St Andrews, 2011) 15, a cytochrome P450 protein (CYP121) from 25	  
Mycobacterium tuberculosis (University of Cambridge, 2012) 16 and a human p53 mutant 26	  
Y220C (Eberhard-Karls-University, and  MRC LMB, Cambridge, 2012) 17. 27	  
 28	  
	   6	  
TSA screening of a 600 fragment rule-of-three compliant library at a concentration of 1 mM, 1	  
identified 38 fragments (~ 6% hit rate) that induced a ΔTm > 1.5 °C in TbINO1 15. Despite the 2	  
relative chemical simplicity of the molecules, several of the TSA hits exhibited trypanocidal 3	  
activity when administered to cultured T. brucei - although for a subset of these hits there were 4	  
also counter indications of mammalian cytotoxicity.  5	  
 6	  
Against CYP121, TSA identified 66 fragment hits from a library of 665 (parameters: 5 mM 7	  
fragment, ΔTm >0.8 °C, ~10 % hit rate), of which 56 of the most chemically diverse fragments 8	  
were rescreened by ligand-detected NMR corroborating the TSA observations for 26 fragments 9	  
(46 % validated hit rate)16.  Four independent ligand-crystal structures were solved revealing 10	  
that each of the fragments bound in an overlapping manner within the relatively large (1350 Å3) 11	  
active site cavity. This allowed the authors to immediately merge the overlapping structural 12	  
moieties to generate a moderate affinity (28 µM) lead compound in a text book application of 13	  
TSA screening, hit validation by orthogonal methods and successful SAR development.  14	  
 15	  
In the case of the cancer associated p53 mutant Y220C, TSA served an elegant duality of 16	  
purpose, simultaneously identifying fragment-target interactions from the library and providing a 17	  
functional read-out (namely rescue of the mutant protein’s reduced Tm and stability at 18	  
physiological temperature 17.) Accordingly TSA was used both in the initial screening stages, 19	  
and as a reporter of functionality in the subsequent SAR efforts.  20	  
 21	  
In addition to the primary screening outlined above, TSA has also been employed to 22	  
characterise hits identified by other methods. For example, in 2011 GlaxoSmithKIine R&D 23	  
applied TSA to assess the selectivity profile of two promising compounds against BET family 24	  
bromodomains relative to other bromodomain containing proteins 18. The compounds, initially 25	  
identified using a fluorescence anisotropy assay, increased the Tm of BET family members by > 26	  
5 °C (consistent with other biophysical indicators of the interaction) relative to a 1.5 °C increase 27	  
in the non-target bromodomain containing proteins, prompting the authors to conclude that 28	  
	   7	  
there may be a “window of selectivity” to exploit. The authors acknowledge that the method 1	  
does not permit precise quantitation of selectivity but this is nevertheless an interesting case 2	  
study in the potential for non-standard applications of the assay in fragment campaigns.  3	  
 4	  
Evidently TSA can be used to interrogate fragment libraries, although the 46 % validation rate 5	  
reported by Hudson et al. 16 raises concerns about the potential for a high false positive rate. It 6	  
is of note that each of the cases described above are proteins that are considered classically 7	  
“druggable” with defined concave target sites, (in the case of p53, one that is induced by the 8	  
Y220C mutation). In the last decade, drug discovery attention has turned to tackling 9	  
protein:protein interactions (PPI), which are highly valuable but certainly less tractable targets. 10	  
PPI targets are challenging because their surfaces are typically flat and shallow, lacking the 11	  
classic defined, concave cavities of what was previously considered the “druggable genome” 19. 12	  
Furthermore, existing small molecule libraries are biased towards previous targets (GPCRs, 13	  
kinases and proteases.) Fragment approaches can overcome this bias, offering diverse 14	  
chemotypes befitting of the new diverse range of targets 20. Fragments may bind into small 15	  
preexisting cavities on the PPI surface, or induce adaptive cavities (perhaps assisted by 16	  
tethering approaches 21,22) to provide “footholds” on the PPI surface 20 for subsequent 17	  
compound development.  18	  
 19	  
However the detection of fragment:PPI interactions is technically challenging. Despite this, two 20	  
recent articles from academic research groups demonstrate beautifully the potential for using 21	  
TSA in FBDD campaigns against PPI. This year Scott et al (University of Cambridge) have 22	  
targeted the interaction between the tumour suppressor BRCA2 and the recombination enzyme 23	  
RAD51 23. The surface area of the interaction is small, involving engagement of Phe and Ala 24	  
side chains from a conserved FXXA motif on one BRC repeat into discrete shallow pockets on 25	  
RAD51 24. For fragment screening, because of the instability of monomeric human RAD51 a 26	  
humanized variant of the archeal orthologue RadA was used. The majority of the fragment 27	  
library (> 60 %) screened by TSA had a neutral effect on the Tm (between - 0.5 and + 0.5 °C), 28	  
	   8	  
22 % gave a negative shift (ΔTm more negative than -0.5 °C), and 3.2 % induced a positive 1	  
ΔTm of >1°C (two standard deviations) of which only two fragments (0.16 %) shifted the Tm by 2	  
more than 1.5 °C. These latter hits were themselves promising, and were also successfully 3	  
used as competitors in subsequent STD NMR re-interrogation of the library and evaluation of 4	  
structural analogues. This paper is an excellent proof of principle in the execution of TSA for 5	  
screening libraries against a challenging PPI interaction.  Despite the shallow nature of the 6	  
binding site, this approach identified fragments exhibiting typical binding affinities (low mM) and 7	  
good ligand efficiency (LE 0.28-0.46), and crystallography confirmed these bound in a manner 8	  
recapitulating the in vivo BRC4 Phe1524-RAD51 interaction. Notably, the authors comment that 9	  
the hit rate (0.16 %) for fragments inducing Tm > 1.5 °C was very low in comparison to similar 10	  
screens against enzyme active sites and indicative of the challenge of such targets 23.  11	  
 12	  
In contrast, Abdel-Rahman et al. (University of Cambridge), in 2011 targeting the Notch ankyrin 13	  
domain using TSA report a healthier hit rate (~ 3 %) for a PPI target, comparable to that 14	  
obtained for other enzyme targets using the same screen 25. Despite the rather flat and 15	  
featureless surface of the ankryin domain, TSA was still able to identify fragments for which 16	  
binding could be confirmed and quantified by SPR and characterized at a molecular level by 17	  
crystallography.  18	  
 19	  
TSA and fragments: potential challenges 20	  
Not every biophysical technique is suitable for every FBDD investigation. As with all methods, 21	  
TSA has its own particular limitations and care should be taken in the interpretation of data, 22	  
particularly with regards to quantifying fragment binding affinity and ranking relative potency.  23	  
For comprehensive discussions on the potential errors in data analysis, the reader is referred to 24	  
excellent articles describing quantitative modelling and analysis of TSA data 4,9,14. Here we 25	  
highlight briefly some of the main challenges that may be commonly encountered.  26	  
 27	  
The magnitude of a Tm shift is affected by the intrinsic binding affinity of the ligand under 28	  
	   9	  
examination. Fragments are relatively small chemicals, that typically bind to proteins with KD 1	  
values in the millimolar range. As a consequence, high concentrations of fragments are often 2	  
necessary to observe a significant shift in Tm 4. However, the high concentrations of fragments 3	  
required for screening can give rise to problems of fragment solubility and aggregation. In 4	  
addition, very weakly binding fragments may be difficult to detect by TSA.  For example, 5	  
fragments identified as having a weakly positive but not significant, effect at 5 mM in the original 6	  
TSA screen against RadA were re-assessed by STD NMR presumably because TSA was an 7	  
insufficiently sensitive method to detect some interactions 23.   It is also of note that the methods 8	  
available for fitting a curve to the raw experimental fluorescence data (the thermodynamic 9	  
model, the Boltzman equation and higher order polynomial equations) can yield different Tm 10	  
values for a given set of data; this discrepancy has been observed to result in fragments being 11	  
differentially classified as a hit or non-hit depending on the model applied 5.  12	  
 13	  
Moreover, fragments may bind at more than one site and may not bind only to the folded state; 14	  
multiple binding events may generate falsely large increases in Tm (if they contribute to protein 15	  
stability in an additive manner) or conversely result in a falsely low Tm shift, if a destabilising 16	  
interaction with the unfolded state negates the stabilising interaction with the folded state. 17	  
Additional technical limitations of TSA stem from the properties of the small molecules or 18	  
fragments themselves. To minimise the likelihood of fluorescence interference, TSA employs a 19	  
red-shifted dye (typically SYPRO-Orange) with an excitation wavelength of ~ 500 nm 3. Despite 20	  
this, optical interference can still be a problem 23,26,27, which we have also observed in our own 21	  
unpublished work. A propensity for non-specific interactions with the fluorescent dye will also 22	  
eliminate fragments from use in the assay. Similarly, not all proteins are compatible with 23	  
SYPRO-Orange. For those cases where no folding transition is observed, or interference is 24	  
apparent, alternative dyes should be investigated. Finally, fragments that induce complex melt 25	  
curves (which may arise from optical interference, compound instability or aggregation 23) must 26	  
also be excluded from further analysis.  27	  
  28	  
	   10	  
In addition to some of the potential difficulties outlined above, attempts to use TSA as a 1	  
secondary interrogation method of NMR hits have on occasion yielded complex results. For 2	  
example, against 3 unnamed kinases, TSA confirmed considerably fewer hits than those 3	  
observed by NMR (23 %, 11 % and 8 % respectively of the initial hits) 28. Notably, for Kinase 3, 4	  
crystal structures were later obtained for protein complexes with NMR hits that were not 5	  
validated by the follow up TSA, calling into question the value of TSA as an orthogonal reporting 6	  
method in this instance. Similarly, of 15 fragments identified by a primary SPR screen against 7	  
PARP15, 14/15 could be validated by NMR but only 1/15 could be confirmed by TSA 13,29.  8	  
 9	  
Throwing out the baby with the bathwater?  10	  
In common with all drug discovery programmes, confirming initial fragment hits in a FBDD 11	  
campaign using independent methods is an essential course of action to increase the likelihood 12	  
of success by reducing the probability of pursuing false positives, with obvious advantages for 13	  
time and economic efficiency. In this article we have discussed instances where secondary 14	  
validation by TSA has given low hit confirmation rates - that were not necessarily indicative of 15	  
the propensity for obtaining fragment bound crystal structures 28 - or produced directly 16	  
conflicting results 13. These observations raise a more general question of how one should 17	  
proceed when orthogonal approaches generate inconclusive or contradictory results.  18	  
Highlighting the potential for disagreement between independent approaches, parallel screening 19	  
of two highly similar fragment libraries (90 % in common) against HIV-integrase 1 using NMR 20	  
and SPR methods respectively, yielded two series of hits which displayed no overlap with each 21	  
other 30 .The lack of overlap was attributed not - as first suspected  - to differences in the 22	  
experimental conditions of each screening approach, but rather to the differing stringency with 23	  
which hits were accepted or rejected. Notably both approaches yielded multiple protein-ligand 24	  
co-crystal structures suitable for future SAR studies, making this example a cautionary tale 25	  
about how nuances in the execution and interpretation of orthogonal approaches to fragment 26	  
interrogation can yield differing results.  27	  
 28	  
	   11	  
Faced with incompatible results, stringent rejection of poorly validated fragments is intuitively 1	  
the more scientifically rigorous course of action. However it carries with it a risk of binary 2	  
interpretation of complex experiments that may report common but also non-redundant 3	  
information, and for which subtle differences in execution or thresholds for interpretation may 4	  
lead to the discarding of potentially valuable fragment hits. On the other hand, retaining poorly 5	  
validated targets may result in wasted efforts (time and money) on false positives. The broad 6	  
applicability of TSA as an orthogonal tool in the drug discovery toolbox is somewhat unclear, 7	  
with conflicting results regarding its usefulness. As highlighted in this article, TSA has been 8	  
used successfully in primary screening efforts against enzymes and PPI - but it has also been 9	  
found “not suitable as a frontline hit-finding method” 28 by others. Notably, in the same article 10	  
secondary characterization of TSA was reported to be generally (although not always) 11	  
predictive of the likelihood of obtaining protein:fragment crystal structures. It is evident that 12	  
because of the potential for optical interference, TSA is not compatible with all compounds 13	  
limiting applicability in both primary screens 23 and secondary characterization 27. Furthermore, 14	  
even among successful TSA investigations there are frequently high rates of neutral Tm shifts 15	  
23,25. These may be true negatives, but may also be false negatives arising from the technical 16	  
challenges of detecting small shifts in Tm associated with low affinity fragment binding 31. 17	  
Rejection of such compounds may reduce the absolute number and chemical diversity of hits, 18	  
with knock-on effects for hit-to-lead progression. The simplicity and high-throughput nature of 19	  
the TSA still make it a highly attractive tool in FBDD programmes, but it is advisable to consider 20	  
the limitations of its applicability before relying upon it solely as a screening method or 21	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Figure 1. A typical thermal shift assay. During a standard experiment the folded (F) globular 5	  
protein is heated in a continuous temperature ramp (typically between 25 and 95 °C) causing it 6	  
to unfold (U). Protein unfolding is reported via an environmentally sensitive dye (e.g. SYPRO® 7	  
Orange, Life Technologies, schematically represented here as a series of hexagons) that 8	  
fluoresces only when bound to hydrophobic regions exposed as the protein unfolds. The protein 9	  
melting temperature (Tm) can be calculated as the inflection of the resulting transition curve 10	  
using a simple Boltzmann equation. Increases in Tm (Δ Tm) between the reference protein 11	  
(solid line) and protein in the presence of a test compound (dashed line) occur as a result of the 12	  
additional free energy contribution of compound binding. 13	  
 14	  
  15	  
	   13	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